Tenax Therapeutics Grants Stock Options to Four New Hires in Talent Push

Tenax Therapeutics Grants Stock Options to Four New Hires in Talent Push

Robert Howard
Robert Howard
2 Min.
Poster stating that in 2022, Big Pharma charged Americans two to three times more than other countries for the same drugs, with images of medication bottles and a syringe.

Tenax Therapeutics Grants Stock Options to Four New Hires in Talent Push

Tenax Therapeutics, Inc. has granted stock options to four new employees as part of their hiring agreements. The company, listed on Nasdaq under the symbol 'TENX', specialises in developing treatments for cardiopulmonary conditions. These awards were approved by an independent board committee to attract key talent.

The inducement awards consist of non-qualified stock options to purchase 657,500 shares of Tenax’s common stock. The options were authorised by the Board’s Compensation Committee, made up entirely of independent directors. Their purpose is to incentivise employees joining the company.

The vesting schedule begins with 25% of the shares becoming exercisable after the first year. The remaining 75% will vest in 36 equal monthly instalments over the following three years. Tenax Therapeutics is a Phase 3 pharmaceutical firm focused on cardiopulmonary therapies. It holds global rights to develop and commercialise levosimendan, including TNX-103, an oral version being tested for PH-HFpEF, a form of heart failure.

The stock options aim to secure long-term commitment from the new hires. Tenax continues to advance its pipeline, with levosimendan-based treatments at the core of its development strategy. The company’s shares remain publicly traded on Nasdaq under 'TENX'.

Neueste Nachrichten